Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$2.22 | -$2.22 | -$2.22 |
Q2 2024 | 1 | -$545.29 | -$545.29 | -$545.29 |
Q3 2024 | 1 | -$433.95 | -$433.95 | -$433.95 |
Q1 2025 | 1 | -$433.95 | -$433.95 | -$433.95 |
Q2 2025 | 1 | -$372.90 | -$372.90 | -$372.90 |
Q1 2026 | 1 | -$0.48 | -$0.48 | -$0.48 |
Q2 2026 | 1 | -$0.43 | -$0.43 | -$0.43 |
Q3 2026 | 1 | -$2.02 | -$2.02 | -$2.02 |
Q4 2026 | 1 | -$0.49 | -$0.49 | -$0.49 |
Q1 2027 | 1 | -$0.44 | -$0.44 | -$0.44 |
Q2 2027 | 1 | -$0.46 | -$0.46 | -$0.46 |
Altamira Therapeutics Ltd. last posted its earnings results on Tuesday, September 24th, 2024. The company reported $-1.98517 earnings per share for the quarter, topping analysts' consensus estimates of $-2.38032 by $0.39515. The company had revenue of 52,735 for the quarter and had revenue of 0 for the year. Altamira Therapeutics Ltd. has generated $-15 earnings per share over the last year ($-14.8 diluted earnings per share) and currently has a price-to-earnings ratio of -0.02. Altamira Therapeutics Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, September 24th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
06/28/2023 | Q2 2023 | -$12.91 | $52,735 | |||
03/30/2023 | Q1 2023 | -$12.97 | $52,735 | |||
05/16/2023 | Q4 2022 | -$2.89 | $0 | |||
09/29/2022 | Q3 2022 | -$199.86 | $-458,691 | |||
11/30/2022 | Q2 2022 | -$106.32 | $145,399 | |||
11/30/2022 | Q1 2022 | -$106.32 | $145,399 | |||
04/12/2022 | Q4 2021 | $164.89 | $0 | |||
09/29/2021 | Q3 2021 | -$149.92 | $0 | |||
03/31/2021 | Q2 2021 | -$438.94 | -$108.47 | 330.47 | $0 | |
03/31/2021 | Q1 2021 | -$438.94 | -$108.47 | 330.47 | $0 | |
03/31/2021 | Q4 2020 | -$438.94 | -$148.91 | 290.03 | $237,000 | |
09/29/2020 | Q3 2020 | -$510.79 | -$148.91 | 361.88 | $0 | |
09/17/2020 | Q2 2020 | -$115.96 | $0 | |||
09/17/2020 | Q1 2020 | -$115.96 | $0 | |||
04/16/2020 | Q4 2019 | -$32.00 | -$83.44 | -51.44 | $-56,000 | |
09/29/2019 | Q3 2019 | $0.00 | $0 | |||
06/30/2019 | Q2 2019 | -$165.85 | $0 | |||
03/30/2019 | Q1 2019 | $0.00 | $0 | |||
03/14/2019 | Q4 2018 | -$485.21 | $1.27 M | |||
09/30/2018 | Q3 2018 | -$569.22 | $0 |
Altamira Therapeutics Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, September 24th, 2024 based off last year's report dates.
In the previous quarter, Altamira Therapeutics Ltd. (:CYTO) reported $-1.98517 earnings per share (EPS) to beat the analysts' consensus estimate of $-2.38032 by $0.39515.
The conference call for Altamira Therapeutics Ltd.'s latest earnings report can be listened to online.
The conference call transcript for Altamira Therapeutics Ltd.'s latest earnings report can be read online.
Altamira Therapeutics Ltd. (:CYTO) has a recorded net income of $0. Altamira Therapeutics Ltd. has generated $-14.81 earnings per share over the last four quarters.
Altamira Therapeutics Ltd. (:CYTO) has a price-to-earnings ratio of -0.02 and price/earnings-to-growth ratio is -0.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED